Mgc Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
Key Metrics
PE ratio
-
PB ratio
2.66
Dividend yield
0.00%
Beta
1.70
Market cap
-
Enterprise value
-
Company profile
| Primary activities | MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines. |
|---|---|
| Industry / Sector | Drug Manufacturers—Specialty & Generic / Healthcare |
| Website | https://mgcpharma.com.au |
| Mailing address | 1202 Hay Street West Perth WA 6005 Australia |
| Phone / Fax | 61 8 6382 3390 / |
| Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Dividends
More: Mgc Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
0.00%
Dividend amount
$0.00
Payout ratio
0.00%
Mgc Pharmaceuticals paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.MXC dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
MXC's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of Aug 2022, following are the company executives and directors listed on Mgc Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Brett Anthony Mitchell B.Ec., MAICD | Exec. Chairman | 48 | 317.4k |
| Mr. Roby Reuven Zomer | Co-Founder, CEO, MD & Exec. Director | 41 | 320.94k |
| Mr. Nativ Segev | Founder & Non-Exec. Director | 79.08k | |
| Ms. Angela-Marie Graham | Group Chief Financial Officer | ||
| Ms. Sasha Friedman | Deputy CEO & COO | ||
| Mr. Amir Polak | Chief Technology Officer | ||
| Ms. Nicole Ann Godresse | Global Chief Sales Officer | ||
| Ms. Sabina Suljakovic | Head of the Quality Assurance Department | ||
| Dr. Nadya Lisodover | Chief Medical Officer | ||
| Yair Tal | Chief Information Security Officer |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-263.50%
Return on assets
-37.85%
Return on equity
-176.11%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Mgc Pharmaceuticals is and its enterprise value is .
The MXC's stocks Beta value is 1.70 making it 70% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Mgc Pharmaceuticals (MXC)
Mgc Pharmaceuticals (ASX:MXC) Frequently Asked Questions
1. What is Mgc Pharmaceuticals's Stock Symbol?
Mgc Pharmaceuticals trades on ASX under the ticker symbol "MXC".
2. What is Mgc Pharmaceuticals's stock price today?
One share of MXC stock can currently be purchased for approximately $0.018.
3. How can I contact Mgc Pharmaceuticals?
Mgc Pharmaceuticals's mailing address is 1202 Hay Street West Perth WA 6005 Australia. The company can be reached via phone at 61 8 6382 3390.
4. What is Mgc Pharmaceuticals's official website?
The official website of Mgc Pharmaceuticals is https://mgcpharma.com.au.
5. Which share registry manages Mgc Pharmaceuticals's stock?
Mgc Pharmaceuticals's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.